SCM
MLYS icon

Silverarc Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Silverarc Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94,983
Closed -$3.45M – 82
2025
Q4 		$3.45M Buy
94,983
+14,983
+19% +$601K 0.48% 48
2025
Q3 		$3.03M Sell
80,000
-35,282
-31% -$763K 0.41% 56
2025
Q2 		$1.56M Sell
115,282
-223,072
-66% -$3.23M 0.29% 49
2025
Q1 		$5.37M Buy
+338,354
New +$3.89M 1.1% 27
2024
Q2 		– Sell
-56,944
Closed -$735K – 81
2024
Q1 		$735K Buy
+56,944
New +$703K 0.2% 66

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Silverarc Capital Management's MLYS Position: Q1 2026 in Review

Silverarc Capital Management sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 94,983 shares — an estimated $3.45M sold.

Silverarc Capital Management first reported a position in MLYS in Q1 2024 and held it in 5 quarters. The position peaked at $5.37M in Q1 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Silverarc Capital Management reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 94,983 Mineralys Therapeutics shares in Q1 2026, an estimated $3.45M.
  • Silverarc Capital Management first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 5 quarters.
  • Silverarc Capital Management's Mineralys Therapeutics position peaked at $5.37M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.